retinal vein occlusion
Conditions
Interventions
control group:placebo
Test group:Take mecobalamin capsules orally
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-80 years old, gender not limited; 2. diagnosed as macular edema secondary to monocular retinal vein occlusion (RVO-ME), and the CFT was confirmed to be >=300µm by OCT; 3. Newly diagnosed patients (who have not received anti-VEGF, glucocorticoid or laser treatment); 4. The baseline BCVA (ETDRS letter count) was 20/400 to 20/40 (34-78 letters); 5. Sign the informed consent form and be able to cooperate with the follow-up and examination;
Exclusion criteria
Exclusion criteria: 1. Combined with other eye diseases that cause macular edema (such as diabetic retinopathy, uveitis, glaucoma, etc.); 2. The presence of severe cataracts, vitreous hemorrhage or refractive medium opacity affects imaging examinations; 3. Systemic use of glucocorticoids or immunosuppressants within 3 months; 4. Severe systemic diseases; 5. allergic to mecobalamin or conbercept; 6. Pregnant or lactating women; 7. Inability to cooperate with examinations or follow-ups (such as mental illness, cognitive impairment); 8. Participate in other clinical trials within one year;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| central foveal thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood vitamin B12 content;Adverse Event (AE);The recurrence rate of macular edema within 12 months and the frequency of anti-VEGF injections;Changes in BCVA compared with the baseline;optical coherence tomography angiography;mfERG;Average light sensitivity of micro-field; | — |
Countries
China
Contacts
Public ContactZhang Yanlai
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed